NCT06596356View on ClinicalTrials.gov

A Mass Balance Study of TS-172 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions
Healthy Male Subjects
Interventions
DRUG

[14C] TS-172

Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT06596356 - A Mass Balance Study of TS-172 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter